Glaxo scientists work to rebuild cancer line-up, funding uncertain
By Ransdell Pierson PHILADELPHIA, Nov 5 (Reuters) - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals. But the British drugmaker has not thrown in the tow
